-+ 0.00%
-+ 0.00%
-+ 0.00%

EQUILLIUM ANNOUNCES FIRST SUBJECT DOSED IN PHASE 1 CLINICAL TRIAL OF EQ504

Reuters·10/26/2026 12:33:06